medicina60巻2号

2023年02月発行

特集 慢性疾患診療のお悩みポイントまとめました—高血圧からヘルスメンテナンスまで 慢性心不全

心不全にSGLT2阻害薬，ARNIって使わないといけないですか？

著者： 平松由布季¹

所属機関： ¹東京ベイ・浦安市川医療センター総合内科

ページ範囲：P.311 - P.316

Point
◎stage C以上（有症状）のHFrEFには，ARNIとSGLT2阻害薬はクラス1で推奨されている．
◎stage C以上（有症状）のHFmrEF, HFpEFには，SGLT2阻害薬のみクラス2aで推奨されている．
◎stage B（無症状）では，ARNIもSGLT2阻害薬もまだ推奨がない．
◎ARNIやSGLT2阻害薬を開始するかどうかは，効果の大きさ，副作用，費用などの情報を提供したうえで，患者と共有意思決定を行う．

参考文献

1）Heidenreich PA, et al：2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure；A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145：e895-e1032, 2022

2）Bozkurt B, et al：Universal definition and classification of heart failure；A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail S1071-9164：00050-6, 2021

3）McMurray JJ, et al：Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371：993-1004, 2014

4）Damman K, et al：Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6：489-498, 2018

5）Vardeny O, et al：Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril；The PARADIGM-HF trial. Eur J Heart Fail 21：337-341, 2019

6）Gaziano TA, et al：Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol 1：666-672, 2016

7）Grant ADM, et al：Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction. CJC Open 2：447-453, 2020

8）Leon SJ, et al：Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD；A population-based cohort study. Am J Kidney Dis 80：164-173 e1, 2022

9）Anker SD, et al：Maintenance of serum potassium with sodium zirconium cyclosilicate（ZS-9）in heart failure patients；Results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail 17：1050-1056, 2015

10）McMurray JJV, et al：Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381：1995-2008, 2019

11）Zannad F, et al：SGLT2 inhibitors in patients with heart failure with reduced ejection fraction；A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396：819-829, 2020

12）Anker SD, et al：Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385：1451-1461, 2021

13）Solomon SD, et al：Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387：1089-1098, 2022

14）Voors AA, et al：The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure；A multinational randomized trial. Nat Med 28：568-574, 2022

15）Kaku K, et al：Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME Trial. Clin Ther 41：2021-2040, 2019

16）Bauersachs J：Heart failure drug treatment；The fantastic four. Eur Heart J 42：681-683, 2021

17）McMurray JJV, Packer M：How should we sequence the treatments for heart failure and a reduced ejection fraction?；A redefinition of evidence-based medicine. Circulation 143：875-877, 2021

18）Tromp J, et al：A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail 10：73-84, 2022

19）American College of Cardiorogy：Drug Options for Patients With Heart Failure.　https://www.cardiosmart.org/assets/decision-aid/drug-options-for-patients-with-heart-failure（2022年10月閲覧）